• Impinj, Inc. recently announced a licensing agreement with EM Microelectronic to integrate its Gen2X technology into future dual-frequency RFID endpoint ICs, which EM expects to bring to market in 2027.
• This partnership extends Impinj’s technology into another chipmaker’s roadmap, potentially broadening its role within the RFID ecosystem and deepening its influence on next-generation tag designs.
• Next, we’ll examine how this Gen2X licensing deal with EM Microelectronic shapes Impinj’s investment narrative and longer-term growth opportunities.

Outshine the giants: these 23 early-stage AI stocks could fund your retirement.

What Is Impinj's Investment Narrative?

To own Impinj, you have to believe RFID adoption can keep expanding and that the company’s Gen2X platform becomes a standard many endpoints are built around. Recent volatility, with the share price down sharply over three months, shows how sensitive the stock is to sentiment around near term growth and profitability, especially as Impinj is currently unprofitable and trades on a rich sales multiple. The EM Microelectronic licensing deal fits into this picture more as a long-dated option than a near term catalyst, given commercialization is not expected until 2027, so it does little to change the upcoming Q4 2025 earnings event as the main near term focus. It may, however, slightly ease concentration risk in Impinj’s own chip roadmap over time.

However, one emerging risk is whether rich expectations still match Impinj’s nearer term execution. Despite retreating, Impinj's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span roughly US$172 to US$241 per share, reflecting very different expectations. Set that against the EM Microelectronic deal’s long timeline and current volatility, and you can see why many readers may want to compare several viewpoints before forming a view on Impinj’s risk and reward trade off.

Explore 2 other fair value estimates on Impinj - why the stock might be worth as much as 44% more than the current price!

Build Your Own Impinj Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Impinj research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Impinj research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Impinj's overall financial health at a glance.

No Opportunity In Impinj?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.